Trial Outcomes & Findings for Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure (NCT NCT04514458)
NCT ID: NCT04514458
Last Updated: 2025-07-01
Results Overview
Assessed as an increase in the number of prescribed targeted evidence-based therapies for HFrEF, including beta-blockers, ACEi, ARBs, ARNIs, MRAs, and SGLT2is.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
1410 participants
Primary outcome timeframe
Assessed from the date of randomization to 30 days post-randomization
Results posted on
2025-07-01
Participant Flow
100 providers were identified and consented to the study. 93 were randomized to the intervention group (alert) (n=46) or to usual care (no alert) group (n=47). This created 93 clusters (providers) to which eligible patient participants were assigned on their first eligible clinic visit. Eligible patient subjects were automatically identified, enrolled and randomized by our best practice alert based on their provider's randomization status (685 to the intervention group and 625 to usual care).
7 provider subjects were excluded prior to randomization as patient recruitment finished before these providers saw an eligible patient.
Participant milestones
| Measure |
EHR-based Alert
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Overall Study
STARTED
|
735
|
675
|
|
Overall Study
Patient Subjects Enrolled
|
685
|
625
|
|
Overall Study
Provider Subjects Enrolled
|
50
|
50
|
|
Overall Study
COMPLETED
|
731
|
672
|
|
Overall Study
NOT COMPLETED
|
4
|
3
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
Baseline characteristics by cohort
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
Total
n=1310 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
72 years
n=5 Participants
|
72 years
n=7 Participants
|
72 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
207 Participants
n=5 Participants
|
195 Participants
n=7 Participants
|
402 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
478 Participants
n=5 Participants
|
430 Participants
n=7 Participants
|
908 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
67 Participants
n=5 Participants
|
58 Participants
n=7 Participants
|
125 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
614 Participants
n=5 Participants
|
559 Participants
n=7 Participants
|
1173 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
9 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
119 Participants
n=5 Participants
|
118 Participants
n=7 Participants
|
237 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
492 Participants
n=5 Participants
|
447 Participants
n=7 Participants
|
939 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
64 Participants
n=5 Participants
|
48 Participants
n=7 Participants
|
112 Participants
n=5 Participants
|
|
Medicaid/Medicare Enrollee
|
535 Participants
n=5 Participants
|
582 Participants
n=7 Participants
|
1117 Participants
n=5 Participants
|
|
Medical History
Atrial Arrhythmias
|
349 Participants
n=5 Participants
|
342 Participants
n=7 Participants
|
691 Participants
n=5 Participants
|
|
Medical History
Coronary Artery Disease (CAD)
|
262 Participants
n=5 Participants
|
208 Participants
n=7 Participants
|
470 Participants
n=5 Participants
|
|
Medical History
Chronic Kidney Disease (CKD)
|
241 Participants
n=5 Participants
|
212 Participants
n=7 Participants
|
453 Participants
n=5 Participants
|
|
Medical History
Depression
|
124 Participants
n=5 Participants
|
99 Participants
n=7 Participants
|
223 Participants
n=5 Participants
|
|
Medical History
Diabetes
|
260 Participants
n=5 Participants
|
235 Participants
n=7 Participants
|
495 Participants
n=5 Participants
|
|
Medical History
Dyslipidemia
|
524 Participants
n=5 Participants
|
500 Participants
n=7 Participants
|
1024 Participants
n=5 Participants
|
|
Medical History
Hypertension
|
583 Participants
n=5 Participants
|
531 Participants
n=7 Participants
|
1114 Participants
n=5 Participants
|
|
Medical History
Obesity
|
145 Participants
n=5 Participants
|
130 Participants
n=7 Participants
|
275 Participants
n=5 Participants
|
|
Medical History
Chronic Pulmonary Disorders
|
202 Participants
n=5 Participants
|
199 Participants
n=7 Participants
|
401 Participants
n=5 Participants
|
|
Medical History
Peripheral Vascular Disease
|
386 Participants
n=5 Participants
|
392 Participants
n=7 Participants
|
778 Participants
n=5 Participants
|
|
Baseline Blood Pressure
Systolic blood pressure
|
120 mmHg
n=5 Participants
|
118 mmHg
n=7 Participants
|
120 mmHg
n=5 Participants
|
|
Baseline Blood Pressure
Diastolic blood pressure
|
70 mmHg
n=5 Participants
|
70 mmHg
n=7 Participants
|
70 mmHg
n=5 Participants
|
|
Baseline Heart Rate
|
74 beats/minute
n=5 Participants
|
74 beats/minute
n=7 Participants
|
74 beats/minute
n=5 Participants
|
|
Patients per provider type
Number of patients seen by physician
|
467 Participants
n=5 Participants
|
438 Participants
n=7 Participants
|
905 Participants
n=5 Participants
|
|
Patients per provider type
Number of patients seen by Advanced Practice Providers
|
218 Participants
n=5 Participants
|
187 Participants
n=7 Participants
|
405 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Beta blockers
|
581 Participants
n=5 Participants
|
517 Participants
n=7 Participants
|
1098 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
ACE-I/ARB/ARNI
|
489 Participants
n=5 Participants
|
437 Participants
n=7 Participants
|
926 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Angiotensin Converting Enzyme Inhibitor (ACE-I)
|
93 Participants
n=5 Participants
|
96 Participants
n=7 Participants
|
189 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Angiotensin Receptor Blocker (ARB)
|
102 Participants
n=5 Participants
|
91 Participants
n=7 Participants
|
193 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Angiotensin Receptor/Neprilysin Inhibitor (ARNI)
|
294 Participants
n=5 Participants
|
250 Participants
n=7 Participants
|
544 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Aldosterone Receptor Antagonist (MRA)
|
193 Participants
n=5 Participants
|
186 Participants
n=7 Participants
|
379 Participants
n=5 Participants
|
|
Number of patients on GDMT classes at baseline
Sodium-Glucose cotransporter-2 inhibitor (SGLT2i)
|
83 Participants
n=5 Participants
|
62 Participants
n=7 Participants
|
145 Participants
n=5 Participants
|
|
Baseline Potassium
|
4.2 mEq/L
n=5 Participants
|
4.3 mEq/L
n=7 Participants
|
4.3 mEq/L
n=5 Participants
|
|
Baseline Creatinine
|
1.2 mg/dL
n=5 Participants
|
1.2 mg/dL
n=7 Participants
|
1.2 mg/dL
n=5 Participants
|
|
Baseline estimated Glomerular Filtration Rate (eGFR)
|
56.9 ml/min/1.73m^2
n=5 Participants
|
58.4 ml/min/1.73m^2
n=7 Participants
|
57.8 ml/min/1.73m^2
n=5 Participants
|
|
Baseline Left Ventricular Ejection Fraction (LVEF)
|
32 percent ejection fraction
n=5 Participants
|
32 percent ejection fraction
n=7 Participants
|
32 percent ejection fraction
n=5 Participants
|
PRIMARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationPopulation: Observed in patient subjects only.
Assessed as an increase in the number of prescribed targeted evidence-based therapies for HFrEF, including beta-blockers, ACEi, ARBs, ARNIs, MRAs, and SGLT2is.
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy
|
176 Participants
|
117 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with prescribed beta blockers
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on Beta Blockers
|
606 Participants
|
521 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with a prescribed ACEi
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on ACE Inhibitors
|
83 Participants
|
92 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with a prescribed ARB
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on ARBs
|
111 Participants
|
85 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with a prescribed ARNI
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on ARNIs
|
334 Participants
|
285 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with a prescribed MRA
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on MRAs
|
232 Participants
|
203 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 30 days post-randomizationAssessed as the number of patients with a prescribed SGLT2i
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Percentage of Patients on SGLT2 Inhibitors
|
144 Participants
|
103 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to the date of death from any cause, up to 365 days post-randomizationAssessed as the number of patients who expired from randomization up to one year from any cause.
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Rate of One-year All-cause Mortality
|
75 Participants
|
68 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomizationNumber of participants with a hospitalization within 30 days of randomization
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Rate of 30-day Hospital Admission
|
47 Participants
|
63 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to the date of ED/ER admission, up to 30 days post-randomizationNumber of participants with an emergency department visit within 30 days of randomization.
Outcome measures
| Measure |
EHR-based Alert
n=685 Participants
Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial): Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
|
Usual Care
n=625 Participants
Providers will not receive an alert and will proceed with usual care.
|
|---|---|---|
|
Rate of 30-day All-cause Emergency Department Visits
|
86 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: Assessed from the date of randomization to 6 months post-randomizationPopulation: The data necessary to analyze this outcome was unable to be released from the university analytics team, therefore we cannot report cost results. The Finance Administration at Yale did not grant approval for access to this data. The data was not collected and will not be accessed in the future.
Assessed as total direct and indirect cost of patient care from randomization to 6 months post randomization.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Proportion of prescriptions filled as assessed by SureScripts
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Assessed at 6 months post-randomizationPopulation: Surescripts data is inaccurate and does not capture all patient prescription fills, thus this data cannot currently be obtained.
Outcome measures
Outcome data not reported
Adverse Events
EHR-based Alert
Serious events: 0 serious events
Other events: 0 other events
Deaths: 75 deaths
Usual Care
Serious events: 0 serious events
Other events: 0 other events
Deaths: 68 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place